CANDEL THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.32 USD | -6.52% |
|
+3.33% | +534.01% |
| 11/04 | Sector Update: Health Care Stocks Decline Thursday Afternoon | MT |
| 11/04 | Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Capitalization 1 | 224.4 | 51.72 | 42.51 | 273.5 |
| Enterprise Value (EV) 1 | 142.3 | 2.512 | 42.51 | 273.5 |
| P/E ratio | -4.09 x | -2.75 x | -1.12 x | -10.2 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 1,795 x | 414 x | - | - |
| EV / Revenue | 1,795 x | 414 x | - | - |
| EV / EBITDA | -88,00,286 x | -15,23,695 x | - | - |
| EV / FCF | -93,27,505 x | -15,80,887 x | - | - |
| FCF Yield | -0% | -0% | - | - |
| Price to Book | 3.5 x | 1.08 x | - | - |
| Nbr of stocks (in thousands) | 28,690 | 28,894 | 28,920 | 29,347 |
| Reference price 2 | 7.820 | 1.790 | 1.470 | 9.320 |
| Announcement Date | 29/03/22 | 30/03/23 | 28/03/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Net sales 1 | 0.125 | 0.125 | - | - |
| EBITDA | -25.49 | -33.94 | - | - |
| EBIT 1 | -25.73 | -34.72 | -38.39 | -46.9 |
| Operating Margin | -20,580.8% | -27,777.6% | - | - |
| Earnings before Tax (EBT) 1 | -36.12 | -18.79 | -37.94 | -41.6 |
| Net income 1 | -36.12 | -18.79 | -37.94 | -41.6 |
| Net margin | -28,899.2% | -15,035.2% | - | - |
| EPS 2 | -1.910 | -0.6500 | -1.310 | -0.9100 |
| Free Cash Flow | -24.05 | -32.72 | - | - |
| FCF margin | -19,242.4% | -26,172.8% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 29/03/22 | 30/03/23 | 28/03/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 | - | - | - | - |
| EBITDA | -8.008 | -7.562 | -8.821 | -8.566 | -8.676 | -7.88 | - | - | - | - |
| EBIT 1 | -8.029 | -7.74 | -8.986 | -8.753 | -8.881 | -8.101 | -9.633 | -9.579 | -8.861 | -10.32 |
| Operating Margin | -25,900% | -24,967.74% | -28,987.1% | -28,235.48% | -28,648.39% | -26,132.26% | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | -5.083 | - | -9.614 | -8.435 | -11.1 |
| Net income 1 | -16.16 | 1.596 | -0.874 | -4.149 | -8.688 | -5.083 | - | -9.614 | -8.435 | -11.1 |
| Net margin | -52,135.48% | 5,148.39% | -2,819.35% | -13,383.87% | -28,025.81% | -16,396.77% | - | - | - | - |
| EPS 2 | -0.6900 | 0.5100 | -0.0300 | -0.1400 | -0.3000 | -0.1700 | -0.3000 | -0.3300 | -0.2900 | -0.3800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/11/21 | 29/03/22 | 12/05/22 | 05/08/22 | 10/11/22 | 30/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 28/03/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | 82.1 | 49.2 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | -24.1 | -32.7 | - | - |
| ROE (net income / shareholders' equity) | -89% | -33.6% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | 2.240 | 1.650 | - | - |
| Cash Flow per Share | -1.180 | -1.090 | - | - |
| Capex | 1.84 | 1.3 | - | - |
| Capex / Sales | 1,468% | 1,037.6% | - | - |
| Announcement Date | 29/03/22 | 30/03/23 | 28/03/24 | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
9.32
USD
Average target price
11
USD
Spread / Average Target
+18.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +534.01% | 274M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- CADL Stock
- Financials Candel Therapeutics, Inc.